Platelet glycoprotein receptors (GP receptors)

Platelet glycoprotein receptors are a diverse group of surface proteins, including Integrin alpha-IIb/beta-3 (GPIIb/IIIa), the GPIb-IX-V complex, and Glycoprotein VI (GPVI), that are essential for the process of hemostasis (UniProt: P08514, P05106). These receptors mediate the adhesion of platelets to the vascular subendothelium—a layer containing collagen and von Willebrand factor (vWF)—following blood vessel injury (PubMed: 15153451). Upon exposure of the subendothelium, GPIb-IX-V binds to vWF for initial tethering, while GPVI interacts with collagen to trigger platelet activation and the subsequent high-affinity binding of GPIIb/IIIa to fibrinogen (NIH: Molecular Basis of Platelet Adhesion). This sequence of events is critical for stopping bleeding but can also lead to pathological arterial thrombosis, which is a primary cause of myocardial infarction and ischemic stroke (StatPearls: Platelet Glycoprotein IIb/IIIa Inhibitors). Therapeutic agents such as Abciximab, Eptifibatide, and Tirofiban target these receptors to prevent ischemic events by blocking the final common pathway of platelet aggregation (PubChem: CID 71311). However, the clinical use of these drugs is limited by significant safety concerns, most notably an increased risk of major systemic bleeding and drug-induced thrombocytopenia (StatPearls: Platelet Glycoprotein IIb/IIIa Inhibitors).

Other names

Platelet membrane glycoproteinsIntegrin alpha-IIb/beta-3GPIIb/IIIaGPIb-IX-V complexGlycoprotein VIGPVI

Inhibition of platelet aggregation by blocking the binding of fibrinogen and von Willebrand factor to glycoprotein receptors, preventing the formation of a stable thrombus.